We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Fluxion Expands Into Asia With First China Sale, Distributors in Korea and Japan
News

Fluxion Expands Into Asia With First China Sale, Distributors in Korea and Japan

Fluxion Expands Into Asia With First China Sale, Distributors in Korea and Japan
News

Fluxion Expands Into Asia With First China Sale, Distributors in Korea and Japan

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Fluxion Expands Into Asia With First China Sale, Distributors in Korea and Japan"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

A second agreement with Novel Science covers sales of both the BioFlux and IonFlux™ platforms in Japan.  Fluxion has also sold its first BioFlux 1000 system into China.  The China Academy of Chinese Medical Science will initially use this system for research on inhibition of thrombus formation on endothelial cells.
 Fluxion’s BioFlux instruments enable live cell image analysis for physiologically-relevant shear flow assays in a standard well-plate format.  Ideal applications include research in cell and platelet adhesion, cancer biology, stem cells and microbial biofilms.  The IonFlux line combines Fluxion’s proprietary microfluidic technology with integrated electronics to automate the traditional patch clamp assay, the “gold standard” in ion channel research.  Ideal drug discovery applications include primary/secondary screening, lead optimization and toxicology screening.

DI Biotech Ltd. is headquartered in Seoul, Korea, and has a branch office in Daejeon City.  DI Biotech has been a market leader and pioneer in Korea's Life Science market.  The company works closely with its customers, with a focus on genomics, molecular biology, peptide synthesis and cell imaging.  S. E. Kim, CEO and President at D.I Biotech comments, “Awareness of the importance of shear stress is increasing among researchers.  The static biological method will move toward more dynamic assays using shear stress control to get closer in vivo data.  I am delighted to introduce technology from Fluxion Bioscience to the Korean market and to our customers in cell biology research.”

Advertisement